- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02608047
Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou
Study Overview
Status
Conditions
Detailed Description
To study the epidemiological and pathogenic of dengue virus in Guangzhou, which help to reveal the regular prevalent pattern and the natural epidemic focus of dengue fever. To establish dengue virus sequence database of Guangzhou region, research the biological characteristics and molecular characteristics of dengue fever epidemic strains especially in 2014 in Guangzhou region, to determine the source and variation of this epidemic strains , which finally help to reveal the cause of the pandemic.
To investigate the serum epidemiology of 7800 large groups of people in 12 county-level cities in Guangzhou by stratified random sampling method. It will enrich the research database of the dengue fever serological antibody level survey of people in Guangzhou. After that the investigators could provide a scientific reference for setting up a risk evaluation and implementation of targeted control measures, and also provide reference for analysis of the epidemic situation in other areas.
To study on molecular markers predictive of severe dengue fever and protective immunity after dengue virus infection. The investigators will obtain both serotype-specific and cross-reactive antibodies, which is highly protective neutralizing antibodies. Then the investigators will explore the potential for clinical application about these neutralizing antibodies. The dengue virus were sequenced which caused dengue fever or severe dengue fever in 2014, and do bioinformatics analysis to find the genetic loci which may be responsible for virulence of dengue virus.
To sum up the clinical and laboratory data of dengue fever in 2014, to carry out the research on the diagnosis and treatment of dengue fever, to explore the effectiveness, safety and mechanism of Integrated Chinese and Western medicine treatment for dengue fever patients,to establish of a more perfect system for the diagnosis and treatment of dengue fever in China.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Recruiting
- Guangzhou NO 8. people's hospital
-
Contact:
- Fuchun Zhang
- Phone Number: 8620-83710219
- Email: gz8hzfc@126.com
-
Contact:
- Lingzhai Zhao
- Phone Number: 8620-83866127
- Email: gz8hzlz@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Dengue patients confirmed by dengue virus NS1 or RNA
Exclusion Criteria:
- Pregnant women
- Fever diseases caused by other viruses
- Combined bacterial infection
- Without complications such as diabetes and tumor.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
dengue patients
Dengue patients confirmed by Non-structural protein and RNA
|
Healthy controls
Healthy population without any diseases
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
All cause severe dengue
Time Frame: One year
|
One year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Fuchun Zhang, Guangzhou NO 8. people's hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201508020263
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dengue Fever
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesMexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic FeverSingapore
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesThailand
-
Sanofi Pasteur, a Sanofi CompanyUnited States Department of DefenseCompletedDengue | Dengue Fever | Dengue Hemorrhagic FeverUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseaseVietnam
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesPeru
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesSingapore
-
U.S. Army Medical Research and Development CommandGlaxoSmithKlineCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Shock SyndromePuerto Rico
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue VirusPuerto Rico, Colombia, Mexico, Honduras
-
SanofiCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue VirusUnited States